GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Debt-to-Asset

CAMP (Camp4 Therapeutics) Debt-to-Asset : 0.34 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Debt-to-Asset?

Camp4 Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $3.10 Mil. Camp4 Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $7.12 Mil. Camp4 Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $29.94 Mil. Camp4 Therapeutics's debt to asset for the quarter that ended in Jun. 2024 was 0.34.

Camp4 Therapeutics Debt-to-Asset Historical Data

The historical data trend for Camp4 Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Debt-to-Asset Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23
Debt-to-Asset
0.12 0.21

Camp4 Therapeutics Quarterly Data
Dec22 Jun23 Dec23 Jun24
Debt-to-Asset 0.12 - 0.21 0.34

Competitive Comparison of Camp4 Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Camp4 Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Debt-to-Asset falls into.


Camp4 Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Camp4 Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.058 + 8.635) / 54.946
=0.21

Camp4 Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.101 + 7.124) / 29.944
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics  (NAS:CAMP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Camp4 Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Camp4 Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Website
https://www.camp4tx.com
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Camp4 Therapeutics Headlines

From GuruFocus

CAMP4 Announces Pricing of Initial Public Offering

By Marketwired • 10-11-2024